SPPI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 liep. 2023 @ 22:56):

Stats
Šios dienos apimtis	4.85M
Vidutinė apimtis	1.64M
Rinkos kapitalizacija	210.38M
EPS	$0 ( 2024-03-20 )
Kita pelno data	( $0 ) 2024-05-07
Last Dividend	$0.150 ( 2012-12-18 )
Next Dividend	$0 ( N/A )
P/E	-2.85
ATR14	$0.0510 (4.95%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-31	Bradrick Brittany	Sell	27 380	Common Stock, $0.001 par value
2023-07-31	Bradrick Brittany	Sell	86 301	Stock Option (Right to Buy)
2023-07-31	Mcgahan Keith M	Sell	195 485	Common Stock, $0.001 par value
2023-07-31	Mcgahan Keith M	Sell	386 057	Common Stock, $0.001 par value
2023-07-31	Mcgahan Keith M	Sell	778 000	Stock Option (Right to Buy)

INSIDER POWER
-27.56
Last 97 transactions
Buy: 24 888 642 \| Sell: 15 180 768

Tūris Koreliacija

Ilgas: 0.14 (neutral)

Trumpas: 0.79 (moderate)

Signal:(56.794) Neutral

Spectrum Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
IRMD	0.941
IDCC	0.939
SLMBP	0.939
DRNA	0.933
PRAA	0.924
MESA	0.923
PIRS	0.923
GALT	0.922
HLIO	0.92
IOAC	0.919

10 Labiausiai neigiamai susiję koreliacijos
GMII	-0.923
AVIR	-0.911
TUEM	-0.907
JRJC	-0.896
AFYA	-0.896
EAR	-0.887
GSMG	-0.885
DTSS	-0.883
ATSG	-0.881
GOEV	-0.88

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Spectrum Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.45
( neutral )

0.29
( neutral )

0.00
( neutral )

0.59
( weak )

0.45
( neutral )

-0.54
( weak negative )

Spectrum Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	$10.11M
Bruto pelnas:	$8.32M (82.28 %)
EPS:	$-0.430

FY	2022
Pajamos:	$10.11M
Bruto pelnas:	$8.32M (82.28 %)
EPS:	$-0.430

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.020

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.290

Financial Reports:

No articles found.

Spectrum Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Spectrum Pharmaceuticals Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.150	2012-12-18
Last Dividend	$0.150	2012-12-18
Next Dividend	$0	N/A
Payout Date	2012-12-28
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.150	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-27)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2012	$0.150	1.02%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-1.400	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.334	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-1.193	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.71	0.800	1.449	1.159	[1 - 3]
quickRatioTTM	2.31	0.800	1.124	0.899	[0.8 - 2.5]
cashRatioTTM	1.347	1.500	3.63	5.44	[0.2 - 2]
debtRatioTTM	0.275	-1.500	5.42	-8.12	[0 - 0.6]
interestCoverageTTM	-19.33	1.000	-8.27	-8.27	[3 - 30]
operatingCashFlowPerShareTTM	-0.320	2.00	-0.107	-0.214	[0 - 30]
freeCashFlowPerShareTTM	-0.322	2.00	-0.161	-0.322	[0 - 20]
debtEquityRatioTTM	1.105	-1.500	5.58	-8.37	[0 - 2.5]
grossProfitMarginTTM	0.889	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-1.481	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-2.18	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.239	0.800	-1.740	-1.392	[0.5 - 2]
Total Score				-3.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-5.75	1.000	-0.682	0	[1 - 100]
returnOnEquityTTM	-1.193	2.50	-9.24	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.322	2.00	-0.107	-0.322	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.320	2.00	-0.107	-0.214	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.583	1.500	9.45	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-2.51	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-1.111

Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.